Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058

Introduction: Understanding the role of opiate dependency treatment in risky sexual behavior could help optimize interventions for people who inject drugs (PWID). Objectives: We evaluated whether long-term medication-assisted treatment (LT-MAT) of opiate dependency with buprenorphine/naloxone influenced risky sexual behavior among HIV-uninfected PWID and identified predictors of risky sexual behavior. Methods: We used data from HPTN 058, a randomized controlled trial of LT-MAT vs. short-term medication-assisted treatment among PWID in China and Thailand. We evaluated associations between randomized opiate dependency treatment group and self-reported risky sexual behaviors within the past month: condomless sex with primary partner, condomless sex with nonprimary partner, multiple partners, and more than 3 sexual acts. We used generalized estimating equations to conduct intention-to-treat, as-treated, and exploratory analyses of these associations. Results: Of 1250 participants included in the analysis, 92% were male, with median age of 34 years (interquartile range 28–39). At baseline, referring to the past month, 36% of participants reported condomless sex with primary partner, 4% reported condomless sex with nonprimary partner, 6% reported multiple sex partners, and 30% reported more than 3 sexual acts. Risky sexual behaviors did not differ significantly between treatment groups at any point. Significant predictors (P < 0.05) of condomless sex with nonprimary partner were history of incarceration and noninjection drug use. Number of needle-sharing partners, noninjection drug use, and higher income were predictors for multiple sexual partners. Conclusions: LT-MAT did not significantly modify risky sexual behavior among HIV-uninfected PWID. Interventions that reduce sexual risk should target PWID with history of incarceration, alcohol use, and needle sharing.

[1]  C. Kerr,et al.  Substance Abuse and Mental Health Services Administration , 2020, Definitions.

[2]  D. Wolfe,et al.  Seeing through the public health smoke-screen in drug policy. , 2017, The International journal on drug policy.

[3]  D. Metzger,et al.  Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058 , 2015, Journal of acquired immune deficiency syndromes.

[4]  D. Metzger,et al.  Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. , 2014, Drug and alcohol dependence.

[5]  W. Ling,et al.  HIV Risk Reduction With Buprenorphine–Naloxone or Methadone: Findings From a Randomized Trial , 2014, Journal of acquired immune deficiency syndromes.

[6]  Sofie Mauger,et al.  Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence , 2014, Neuropsychiatric disease and treatment.

[7]  Khodabakhsh Ahmadi,et al.  Inconsistent Condom Use among Iranian Male Drug Injectors , 2014, Front. Psychiatry.

[8]  W. Mcfarland,et al.  Risk behaviors for HIV in sexual partnerships of San Francisco injection drug users , 2014, AIDS care.

[9]  Khodabakhsh Ahmadi,et al.  Having Multiple Sexual Partners among Iranian Intra-Venous Drug Users , 2013, Front. Psychiatry.

[10]  Y. Ruan,et al.  Prevalence and correlates of sexual risk behaviors among drug users in western China: implications for HIV transmission. , 2013, AIDS research and human retroviruses.

[11]  H. Xing,et al.  Evaluation of Harm Reduction Programs on Seroincidence of HIV, Hepatitis B and C, and Syphilis Among Intravenous Drug Users in Southwest China , 2013, Sexually transmitted diseases.

[12]  L. Degenhardt,et al.  Mitigating the risk of HIV infection with opioid substitution treatment. , 2013, Bulletin of the World Health Organization.

[13]  T. Flanigan,et al.  Participant Characteristics and HIV Risk Behaviors Among Individuals Entering Integrated Buprenorphine/Naloxone and HIV Care , 2011, Journal of acquired immune deficiency syndromes.

[14]  G. Fitzmaurice,et al.  HIV Risk Behavior in Treatment-Seeking Opioid-Dependent Youth: Results From a NIDA Clinical Trials Network Multisite Study , 2010, Journal of acquired immune deficiency syndromes.

[15]  Connie Lim,et al.  Youth risk behavior surveillance - United States, 2009. , 2010, Morbidity and mortality weekly report. Surveillance summaries.

[16]  David E. Smith,et al.  Buprenorphine in the Treatment of Opiate Dependence , 2010, Journal of psychoactive drugs.

[17]  D. Vlahov,et al.  Prevention of HIV infection among injection drug users in resource-limited settings. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  T. Ha,et al.  The Chinese government's response to drug use and HIV/AIDS: A review of policies and programs , 2010, Harm reduction journal.

[19]  D. D. Des Jarlais,et al.  At-risk drinking and injection and sexual risk behaviors of HIV-positive injection drug users entering drug treatment in New York City. , 2009, AIDS patient care and STDs.

[20]  R. Weiss,et al.  HIV risk behavior in opioid dependent adults seeking detoxification treatment: an exploratory comparison of heroin and oxycodone users. , 2009, The American journal on addictions.

[21]  C. Latkin,et al.  Social injecting and other correlates of high-risk sexual activity among injecting drug users in northern Vietnam. , 2009, The International journal on drug policy.

[22]  D. D. Des Jarlais,et al.  HIV Testing and Treatment Among At-Risk Drinking Injection Drug Users , 2009, Journal of the International Association of Physicians in AIDS Care.

[23]  D. D. Des Jarlais,et al.  Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. , 2009, Drug and alcohol dependence.

[24]  Ning Wang,et al.  Sexual behavior and risks for HIV infection and transmission among male injecting drug users in Yunnan, China. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[25]  John E. Anderson,et al.  Trends in sexual risk behavior and unprotected sex among high school students, 1991-2005: the role of substance use. , 2008, The Journal of school health.

[26]  Declan T. Barry,et al.  Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. , 2008, Journal of substance abuse treatment.

[27]  Min Zhao,et al.  HIV sexual risk behaviors among injection drug users in Shanghai. , 2006, Drug and alcohol dependence.

[28]  Y. Ruan,et al.  Injection drug use and HIV/AIDS in China: Review of current situation, prevention and policy implications , 2006, Harm reduction journal.

[29]  D. Fiellin,et al.  Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  D. Vlahov,et al.  Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy , 2005, AIDS and Behavior.

[31]  L. Degenhardt,et al.  Drug use and risk behaviours among injecting drug users: a comparison between sex workers and non-sex workers in Sydney, Australia , 2005, Harm reduction journal.

[32]  L. O'donnell,et al.  Early alcohol initiation and subsequent sexual and alcohol risk behaviors among urban youths. , 2005, American journal of public health.

[33]  Shubulade Smith Drugs that cause sexual dysfunction. , 2004, The Medical letter on drugs and therapeutics.

[34]  M. Stein,et al.  Intravenous Drug Users' HIV‐Risk Behaviors with Primary/Other Partners , 2004, The American journal of drug and alcohol abuse.

[35]  D. Metzger,et al.  HIV prevention among injection drug users: The need for integrated models , 2003, Journal of Urban Health.

[36]  M. Esteves,et al.  A Study of the Sexuality of Opiate Addicts , 2002, Journal of sex & marital therapy.

[37]  M. Schechter,et al.  Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control , 2002, Sexually transmitted infections.

[38]  D. Vlahov,et al.  Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users , 2001, AIDS.

[39]  M. Brandeau,et al.  The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. , 2001, Addiction.

[40]  R. Booth,et al.  Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. , 2000, Drug and alcohol dependence.

[41]  J. Catania A framework for conceptualizing reporting bias and its antecedents in interviews assessing human sexuality , 1999 .

[42]  C. Latkin,et al.  Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users' networks. , 1998, Public health reports.

[43]  S. M. Rogers,et al.  Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. , 1998, Science.

[44]  J L Collins,et al.  Youth risk behavior surveillance--United States, 1993. , 1995, The Journal of school health.

[45]  J. Catania,et al.  Methodological problems in AIDS behavioral research: influences on measurement error and participation bias in studies of sexual behavior. , 1990, Psychological bulletin.

[46]  M M Fanning,et al.  Validity of sexual histories in a prospective study of male sexual contacts of men with AIDS or an AIDS-related condition. , 1988, American journal of epidemiology.

[47]  Christopher E. Smith United States , 1985, The Lancet.

[48]  J. Mendelson,et al.  Opiate use and sexual function. , 1980, The American journal of psychiatry.

[49]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[50]  A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2004) State Council AIDS Working Committee Office , 2004 .